Morgan Stanley Assumes Disc Medicine at Overweight, Announces Price Target of $85

Benzinga · 07/03 17:41
Morgan Stanley analyst Sean Laaman assumes Disc Medicine (NASDAQ:IRON) with a Overweight rating and announces Price Target of $85.